Avalo CSO reports small tax share disposition

Avalo Therapeutics, Inc. Chief Strategy Officer Jennifer Riley reported a small administrative share disposition related to tax withholding.

Rhea-AI Filing Summary

Avalo Therapeutics, Inc. Chief Strategy Officer Jennifer Riley reported a small administrative share disposition related to tax withholding. On June 10, 2026, 588 shares of Common Stock were withheld at $13.10 per share to cover tax obligations, rather than sold on the open market.

After this transaction, Riley directly holds 39,696 shares of Avalo Therapeutics common stock. This balance includes 3,429 shares acquired through the company’s Employee Stock Purchase Plan as part of the same reporting event, highlighting that the filing reflects routine compensation and tax mechanics.

Insider Trade Summary

Exercise Price or Tax Liability: 588 shares

Exercise Price or Tax Liability 1 txn

Insider Riley Jennifer

Role Chief Strategy Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	588	$13.10	$8K

Holdings After Transaction: Common Stock — 39,696 shares (Direct)

Footnotes (1)

1. F1. Includes 3,429 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as a part of this reporting transaction.

Key Figures

Tax-withholding shares: 588 shares Withholding price: $13.10 per share Post-transaction holdings: 39,696 shares +1 more

4 metrics

Tax-withholding shares 588 shares Common Stock withheld for taxes on Jun. 10, 2026

Withholding price $13.10 per share Value used for tax-withholding disposition

Post-transaction holdings 39,696 shares Directly held Avalo Therapeutics common stock after transaction

ESPP shares included 3,429 shares Acquired via Employee Stock Purchase Plan in this event

Key Terms

tax-withholding disposition, Employee Stock Purchase Plan, Common Stock

3 terms

tax-withholding disposition financial

"588 shares of Common Stock were withheld to cover tax obligations"

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

Employee Stock Purchase Plan financial

"Includes 3,429 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

Common Stock financial

"588 shares of Common Stock were withheld at $13.10 per share"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Avalo Therapeutics (AVTX) report for Jennifer Riley?

Avalo Therapeutics reported that Chief Strategy Officer Jennifer Riley had 588 shares withheld to cover tax obligations. The shares were valued at $13.10 each, reflecting a routine tax-withholding disposition rather than an open-market sale.

Did Jennifer Riley sell Avalo Therapeutics (AVTX) shares on the open market?

No, the filing shows a tax-withholding disposition of 588 shares at $13.10 per share. These shares were used to satisfy tax liabilities associated with equity compensation, not sold in an open-market transaction to another investor.

How many Avalo Therapeutics (AVTX) shares does Jennifer Riley hold after the Form 4 transaction?

Following the reported tax-withholding disposition, Jennifer Riley directly holds 39,696 shares of Avalo Therapeutics common stock. This total includes shares from the company’s Employee Stock Purchase Plan as noted in the Form 4 footnote disclosure.

What role does the Employee Stock Purchase Plan play in this Avalo Therapeutics (AVTX) filing?

The Form 4 footnote states that Riley’s holdings include 3,429 shares acquired under Avalo’s Employee Stock Purchase Plan. These ESPP shares were part of the same reporting event, illustrating ongoing participation in the company’s employee equity programs.

How many shares were used for tax withholding in the Avalo Therapeutics (AVTX) Form 4?

The Form 4 identifies 588 shares of Avalo Therapeutics common stock as a tax-withholding disposition. These shares were valued at $13.10 each and delivered to satisfy tax liabilities tied to equity compensation, classified under transaction code F.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 04:43 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Riley Jennifer

(Last) (First) (Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Strategy Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/10/2026		F		588	D	$13.1	39,696(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes 3,429 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as a part of this reporting transaction.

	/s/ Christopher Sullivan, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)